Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings

Autor:	Daniel Morgensztern, Xiaoxing Cui, Toana Kawashima, Bill Arana, George E. Peoples, Rachel E. Sanborn, Nathan A. Pennell, Wael A. Harb, Roger B. Cohen, Lyudmila Bazhenova
Rok vydání:	2021
Předmět:	Oncology Cancer Research medicine.medical_specialty Multiple cancer Allogeneic cell business.industry non-small cell lung cancer (NSCLC) medicine.disease Human lung medicine.anatomical_structure Antigen Internal medicine medicine Nivolumab Viagenpumatucel-L business Previously treated
Zdroj:	Journal of Clinical Oncology. 39:9100-9100
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2021.39.15_suppl.9100
Popis:	9100 Background: Viagenpumatucel-L (HS-110) is an allogeneic cell therapy derived from a human lung adenocarcinoma cell line incorporating multiple cancer testis antigens and transfected with a gp96-Ig fusion protein. Methods: We report interim results of cohort A (previously treated pts who had not received a checkpoint inhibitor [CPI]) and cohort B (pts who progressed after CPI treatment) in an ongoing phase 2 trial evaluating HS-110 plus nivolumab (NIVO) in advanced NSCLC pts (NCT02439450). Pts received HS-110 (1×107 cells) intradermally QW for 18 wk and NIVO Q2W until tumor progression. Stratified analyses were performed by injection site reaction (ISR), yes (+) or no (–); baseline blood tumor mutational burden (bTMB), bTMB-L (5% of pts included fatigue, maculopapular rash, nausea, diarrhea, and pruritus. Few HS-110–related TEAEs led to discontinuation of treatment [cohort A, 5 (10.6%); cohort B, 3 (4.4%)], and no serious AEs were considered related to HS-110. Conclusions: HS-110 was well tolerated when administered in combination with NIVO. In previously treated pts with advanced NSCLC, we observed (1) significantly longer PFS and OS in ISR+ pts in both CPI naïve and CPI progressor cohorts; (2) significantly longer OS in PD-L1+ patients in the CPI naïve cohort; and (3) a trend of improved OS in bTMB-L pts in the CPI progressor cohort. Further clinical evaluation of HS-110 is warranted in both CPI naïve and CPI progressor NSCLC patients. Clinical trial information: NCT02439450. [Table: see text]
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a7ff2281b091855584c909263c9f4ed6 https://doi.org/10.1200/jco.2021.39.15_suppl.9100 Zobrazit plný text záznamu